FDA Orders Eye-Damage Warning on Ozempic, Wegovy, Mounjaro and Zepbound Labels

The U.S. Food and Drug Administration (FDA) on Monday, November 9, 2026, ordered makers of the blockbuster weight-loss and diabetes drugs Ozempic, Wegovy, Mounjaro, and Zepbound to add a new warning to their labels: the medicines carry a potential increased risk of a rare but serious eye condition that can cause sudden, painless vision loss, including permanent loss of sight in one eye.

The requirement applies to the entire class of glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, and every manufacturer must add the warning to the Warnings and Precautions section of its labeling, the FDA said in a Drug Safety Communication issued Monday. The drugs are among the most widely prescribed medicines in the United States, used by millions of people for type 2 diabetes and weight management.

The short answer: The FDA is requiring all GLP-1 drugs — including Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Victoza, and Saxenda — to carry a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless vision loss in one eye. The drugs are not being recalled or withdrawn; the FDA says patients should report any sudden vision change immediately and seek prompt referral to an eye specialist.

What Is NAION, and Why Is the FDA Acting Now?

NAION — non-arteritic anterior ischemic optic neuropathy — is a rare condition in which blood flow to the optic nerve is reduced, damaging the nerve and causing sudden, painless loss of vision in one eye. It is a common cause of sudden vision loss in adults over 50, and in some cases the vision loss is permanent. The FDA puts the background rate of NAION at 2.3 to 10.2 cases per 100,000 people per year in adults older than 50.

The FDA began its review after a study published in July 2024 in JAMA Ophthalmology, by Dr. Jimena Tatiana Hathaway and colleagues, reported a potential link between the diabetes drug semaglutide and NAION. The agency then reviewed evidence from six data streams, including a meta-analysis of 126 randomized controlled trials enrolling 134,253 patients and covering 288,879 person-years of exposure.

What the Evidence Showed

In the pooled clinical trial data, investigators identified 15 probable NAION events: 10 in patients who received a GLP-1 drug, five in patients who received a placebo, and none in patients who received another type of glucose-lowering drug. The rate was 6.4 events per 100,000 person-years on a GLP-1 drug, compared with 3.8 per 100,000 person-years on a comparator drug.

The FDA was candid that no single data source settled the matter. In a separate real-world study using the agency's Sentinel system, which followed adults with type 2 diabetes who started a GLP-1 drug, an SGLT-2 inhibitor, or a DPP-4 inhibitor between 2019 and 2024, the crude rate of NAION was similar across all three groups, at roughly 26 to 32 cases per 100,000 person-years. An analysis of animal data found no mechanism by which GLP-1 drugs would increase the risk. But cases of NAION have now been reported for every GLP-1 drug currently on the market, and on the totality of the evidence the FDA concluded there is a potential increased risk — enough to require a class-wide label warning.

Which Drugs Are Affected?

The labeling requirement covers every medicine with GLP-1 receptor agonist activity. That includes semaglutide — sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss, all made by Novo Nordisk — and tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly. It also covers liraglutide (Victoza and Saxenda), dulaglutide (Trulicity), exenatide, lixisenatide (Soliqua), and orforglipron (Foundayo), an oral drug approved earlier in 2026.

The FDA stressed that the communication requires a labeling change only. It does not withdraw, recall, or restrict any product, and patients should not stop taking their medicine on their own. The agency advises health care professionals to tell patients to immediately report any sudden onset of acute, painless loss of vision, visual field deficits, or other visual disturbances in one eye — and to refer patients with suspected NAION promptly to an ophthalmologist. If NAION is suspected, the FDA says, doctors should consider stopping the GLP-1 drug unless the benefits of treatment clearly outweigh the risk.

What This Means for Patients

Last year, the European Medicines Agency's safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year — a reminder that the condition is rare even as the drugs are used by tens of millions of people worldwide. Risk factors the FDA lists for NAION include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease — conditions that are common among the very patients prescribed GLP-1 drugs, which makes the warning especially important for prescribers to discuss.

The announcement lands in a year of intense scrutiny for the GLP-1 class, as Washington debates drug prices and access — part of the same political moment covered in our report on President Trump's post-midterm reckoning. For patients, the practical message is simple: know the warning sign — sudden, painless vision loss in one eye — and act on it the same day. Read more health and wellness updates here.

Read Also:

• Trump Admits Deportation Crackdown Was "Too Tough" After Midterm Losses
• Jeffries Is a "Hard Yes" on Impeaching Hegseth

Frequently Asked Questions

What warning is the FDA adding to Ozempic, Wegovy, Mounjaro, and Zepbound?

The FDA is requiring all GLP-1 drugs to add a warning to the Warnings and Precautions section of their labels about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss.

Is the FDA recalling Ozempic or Wegovy?

No. The FDA's November 9, 2026, Drug Safety Communication requires a labeling change only. It does not withdraw, recall, or restrict any GLP-1 product, and patients should not stop taking their medicine without talking to their doctor.

What is NAION?

NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the optic nerve is reduced, damaging the nerve. It causes sudden, painless loss of vision in one eye and is a common cause of sudden vision loss in adults over 50. In some cases the vision loss is permanent.

How common is NAION in people taking GLP-1 drugs?

It is rare. In the FDA's pooled analysis of 126 clinical trials, there were 15 probable NAION events among 134,253 patients — 10 in patients on a GLP-1 drug and five on placebo — a rate of 6.4 events per 100,000 person-years on GLP-1 drugs versus 3.8 on a comparator. The European Medicines Agency has said NAION may affect up to 1 in 10,000 people taking semaglutide for at least one year.

What should I do if I take a GLP-1 drug and notice vision changes?

The FDA advises patients to immediately report any sudden onset of acute, painless loss of vision, visual field deficits, or other visual disturbances in one eye, and to seek prompt referral to an ophthalmologist. Doctors should consider stopping the GLP-1 drug if NAION develops, unless the benefits of treatment clearly outweigh the risk.

Which drugs does the FDA warning cover?

The warning applies to the whole GLP-1 class: semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide, lixisenatide (Soliqua), and orforglipron (Foundayo). Cases of NAION have been reported for all currently marketed GLP-1 products.